{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-018402","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.872921+00:00","generated_at":"2026-05-26T22:50:20.367277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alkermes reports FY2024 revenue $1.56B, net income $372M; guides FY2025 rev $1.34-$1.43B","bullets":["FY2024 total revenues $1.56B, proprietary net sales up 18% YoY to $1.08B; GAAP diluted EPS from cont. ops $2.20.","Q4 proprietary net sales $307.7M: LYBALVI $77M (+37%), ARISTADA $96.6M (+16%), VIVITROL $134.1M (+31%).","Year-end cash/investments $824.8M; debt-free after retiring $290M debt; repurchased $200M shares in 2024.","FY2025 guidance: rev $1.34-$1.43B, GAAP net income $175-$205M, R&D spend up to $335M for pipeline.","ALKS 2680 Phase 2 narcolepsy data expected H2 2025; Phase 2 in idiopathic hypersomnia planned; ALKS 4510/7290 Phase 1 starts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-018402","json":"https://secwatch.observer/filing/0000950170-25-018402.json","markdown":"https://secwatch.observer/filing/0000950170-25-018402.md","text":"https://secwatch.observer/filing/0000950170-25-018402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/0000950170-25-018402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/alks-20250212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:50:20.367277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}